Mepolizumab - a novel option for the treatment of hypereosinophilic syndrome in childhood

Background Mepolizumab was originally intended as a therapeutic agent for atopic asthma in adults, and consequently little is known about its use in children. Up to now corticosteroids have formed the basis of the initial treatment of hypereosinophilic syndromes and are shown to be effective in most patients. To analyse the effect of mepolizumab in children is the aim of this study. Methods We are reporting the experience of the effect of mepolizumab in two paediatric patients of hypereosinophilic syndrome that was not sufficiently controlled by other drugs. In addition, the literature regarding the treatment with mepolizumab in paediatric and adult patients is reviewed for the most important studies regarding safety and efficacy. Results Mepolizumab therapy showed in two paediatric patients with severe hypereosinophilic syndrome a safe and efficient therapeutic approach. No significant intolerances appeared. Furthermore, treatment with systemic corticosteroids was terminated, and therefore severe side effects were avoided in our pediatric cases. Conclusions Anti-IL-5 antibodies, which can be applied without substantial drug intolerances, are a new, safe and effective treatment option for paediatric patients with hypereosinophilic syndrome. This article is protected by copyright. All rights reserved.